Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

2.1 Olaparib (Lynparza, AstraZeneca) has a marketing authorisation as a 'monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2‑mutations who have HER2‑negative, high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics for olaparib.

2.3 The list price is £2,317.50 per 56‑pack of 150 mg tablets (excluding VAT; BNF online accessed January 2023).

2.4 The company has a commercial arrangement. This makes olaparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.